{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:38:43Z","timestamp":1784209123716,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,4,25]],"date-time":"2015-04-25T00:00:00Z","timestamp":1429920000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s40262-015-0269-z","type":"journal-article","created":{"date-parts":[[2015,4,24]],"date-time":"2015-04-24T11:06:06Z","timestamp":1429873566000},"page":"1151-1160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole"],"prefix":"10.1007","volume":"54","author":[{"given":"Kim","family":"Vanstraelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Augustijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Lagrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"de Loor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raf","family":"Mols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Annaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Malfroot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,25]]},"reference":[{"issue":"2","key":"269_CR1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","volume":"46","author":"A Pascual","year":"2008","unstructured":"Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201\u201311.","journal-title":"Clin Infect Dis."},{"issue":"8","key":"269_CR2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","volume":"55","author":"WB Park","year":"2012","unstructured":"Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55(8):1080\u20137.","journal-title":"Clin Infect Dis."},{"issue":"10","key":"269_CR3","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/AAC.00707-13","volume":"57","author":"KC Elst van der","year":"2013","unstructured":"van der Elst KC, Span LF, van Hateren K, Vermeulen KM, van der Werf TS, Greijdanus B, et al. Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. Antimicrob Agents Chemother. 2013;57(10):4999\u20135004.","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"269_CR4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejps.2004.04.010","volume":"22","author":"B Leboulanger","year":"2004","unstructured":"Leboulanger B, Guy RH, Delgado-Charro MB. Non-invasive monitoring of phenytoin by reverse iontophoresis. Eur J Pharm Sci. 2004;22(5):427\u201333.","journal-title":"Eur J Pharm Sci."},{"issue":"1","key":"269_CR5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FTD.0b013e31827c11e7","volume":"35","author":"PN Patsalos","year":"2013","unstructured":"Patsalos PN, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Ther Drug Monit. 2013;35(1):4\u201329.","journal-title":"Ther Drug Monit."},{"issue":"2","key":"269_CR6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1373\/clinchem.2013.209676","volume":"60","author":"S Anizan","year":"2014","unstructured":"Anizan S, Huestis MA. The potential role of oral fluid in antidoping testing. Clin Chem. 2014;60(2):307\u201322.","journal-title":"Clin Chem."},{"key":"269_CR7","volume-title":"Clarke\u2019s analytical forensic toxicology","author":"A Negrusz","year":"2008","unstructured":"Negrusz A, Cooper G. Clarke\u2019s analytical forensic toxicology. 2nd ed. London: Pharmaceutical Press; 2008.","edition":"2"},{"issue":"3","key":"269_CR8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/FTD.0b013e318283eaf2","volume":"35","author":"DS Fisher","year":"2013","unstructured":"Fisher DS, van Schalkwyk GI, Seedat S, Curran SR, Flanagan RJ. Plasma, oral fluid, and whole-blood distribution of antipsychotics and metabolites in clinical samples. Ther Drug Monit. 2013;35(3):345\u201351.","journal-title":"Ther Drug Monit."},{"issue":"1","key":"269_CR9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/bmc.1103","volume":"23","author":"R Mullangi","year":"2009","unstructured":"Mullangi R, Agrawal S, Srinivas NR. Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives. Biomed Chromatogr. 2009;23(1):3\u201325.","journal-title":"Biomed Chromatogr."},{"key":"269_CR10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cca.2014.06.002","volume":"436","author":"MD Krasowski","year":"2014","unstructured":"Krasowski MD, McMillin GA. Advances in anti-epileptic drug testing. Clin Chim Acta. 2014;436:224\u201336.","journal-title":"Clin Chim Acta."},{"issue":"8","key":"269_CR11","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1128\/AAC.00558-13","volume":"57","author":"MS Bolhuis","year":"2013","unstructured":"Bolhuis MS, van Altena R, van Hateren K, de Lange WC, Greijdanus B, Uges DR, et al. Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57(8):3676\u201380.","journal-title":"Antimicrob Agents Chemother."},{"key":"269_CR12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/1471-2334-14-473","volume":"14","author":"M Lamorde","year":"2014","unstructured":"Lamorde M, Fillekes Q, Sigaloff K, Kityo C, Buzibye A, Kayiwa J, et al. Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography technique. BMC Infect Dis. 2014;14:473.","journal-title":"BMC Infect Dis."},{"key":"269_CR13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jchromb.2014.04.019","volume":"960","author":"SR Bista","year":"2014","unstructured":"Bista SR, Lobb M, Haywood A, Hardy J, Tapuni A, Norris R. Development, validation and application of an HPLC\u2013MS\/MS method for the determination of fentanyl and nor-fentanyl in human plasma and saliva. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;960:27\u201333.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"issue":"2","key":"269_CR14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/FTD.0b013e3182492a20","volume":"34","author":"RI Henkin","year":"2012","unstructured":"Henkin RI. Comparative monitoring of oral theophylline treatment in blood serum, saliva, and nasal mucus. Ther Drug Monit. 2012;34(2):217\u201321.","journal-title":"Ther Drug Monit."},{"issue":"1\u20133","key":"269_CR15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.forsciint.2009.12.038","volume":"196","author":"E Marchei","year":"2010","unstructured":"Marchei E, Farre M, Pellegrini M, Garcia-Algar O, Vall O, Pacifici R, et al. Pharmacokinetics of methylphenidate in oral fluid and sweat of a pediatric subject. Forensic Sci Int. 2010;196(1\u20133):59\u201363.","journal-title":"Forensic Sci Int."},{"issue":"11","key":"269_CR16","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1128\/AAC.03636-14","volume":"58","author":"KC Elst van der","year":"2014","unstructured":"van der Elst KC, van Alst M, Lub-de Hooge MN, van Hateren K, Kosterink JG, Alffenaar JW, et al. Clinical validation of the analysis of fluconazole in oral fluid in hospitalized children. Antimicrob Agents Chemother. 2014;58(11):6742\u20136.","journal-title":"Antimicrob Agents Chemother."},{"issue":"8","key":"269_CR17","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/jps.24064","volume":"103","author":"K Vanstraelen","year":"2014","unstructured":"Vanstraelen K, Wauters J, deLoor H, Vercammen I, Annaert P, Lagrou K, et al. Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis. J Pharm Sci. 2014;103(8):2565\u201370.","journal-title":"J Pharm Sci."},{"key":"269_CR18","doi-asserted-by":"crossref","first-page":"D901","DOI":"10.1093\/nar\/gkm958","volume":"36","author":"DS Wishart","year":"2008","unstructured":"Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36:D901\u20136.","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"269_CR19","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","volume":"46","author":"L Purkins","year":"2002","unstructured":"Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46(8):2546\u201353.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"269_CR20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/FTD.0b013e3181cff20d","volume":"32","author":"C Michael","year":"2010","unstructured":"Michael C, Bierbach U, Frenzel K, Lange T, Basara N, Niederwieser D, et al. Determination of saliva trough levels for monitoring voriconazole therapy in immunocompromised children and adults. Ther Drug Monit. 2010;32(2):194\u20139.","journal-title":"Ther Drug Monit."},{"key":"269_CR21","unstructured":"Vfend prescribing information. 2011. Available from: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=618 . Accessed 20 Dec 2014."},{"issue":"11","key":"269_CR22","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1128\/AAC.03641-14","volume":"58","author":"K Vanstraelen","year":"2014","unstructured":"Vanstraelen K, Wauters J, Vercammen I, deLoor H, Maertens J, Lagrou K, et al. Impact of hypoalbuminemia on voriconazole pharmacokinetics in adult critically ill patients. Antimicrob Agents Chemother. 2014;58(11):6782\u20139.","journal-title":"Antimicrob Agents Chemother."},{"key":"269_CR23","doi-asserted-by":"crossref","DOI":"10.1201\/9781420035889","volume-title":"Topics in modelling of clustered data","author":"M Aerts","year":"2002","unstructured":"Aerts M, Geys H, Molenberghs G, Ryan LM. Topics in modelling of clustered data. London: CRC\/Chapman & Hall; 2002."},{"issue":"2","key":"269_CR24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1191\/096228099673819272","volume":"8","author":"JM Bland","year":"1999","unstructured":"Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8(2):135\u201360.","journal-title":"Stat Methods Med Res."},{"issue":"1","key":"269_CR25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/dmd.109.029769","volume":"38","author":"SB Yanni","year":"2010","unstructured":"Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK Jr, Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase\u00a03. Drug Metab Dispos. 2010;38(1):25\u201331.","journal-title":"Drug Metab Dispos."},{"issue":"2","key":"269_CR26","first-page":"203","volume":"30","author":"OH Drummer","year":"2008","unstructured":"Drummer OH. Introduction and review of collection techniques and applications of drug testing of oral fluid. Ther Drug Monit. 2008;30(2):203\u20136.","journal-title":"Ther Drug Monit."},{"issue":"6","key":"269_CR27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003088-199936060-00006","volume":"36","author":"H Liu","year":"1999","unstructured":"Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples: focus on anticonvulsants. Clin Pharmacokinet. 1999;36(6):453\u201370.","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"269_CR28","doi-asserted-by":"crossref","first-page":"e86204","DOI":"10.1371\/journal.pone.0086204","volume":"9","author":"J Moeller","year":"2014","unstructured":"Moeller J, Lieb R, Meyer AH, Loetscher KQ, Krastel B, Meinlschmidt G. Improving ambulatory saliva-sampling compliance in pregnant women: a randomized controlled study. PLoS One. 2014;9(1):e86204.","journal-title":"PLoS One."},{"issue":"1","key":"269_CR29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00007691-198503000-00006","volume":"7","author":"RG Dickinson","year":"1985","unstructured":"Dickinson RG, Hooper WD, King AR, Eadie MJ. Fallacious results from measuring salivary carbamazepine concentrations. Ther Drug Monit. 1985;7(1):41\u20135.","journal-title":"Ther Drug Monit."},{"issue":"8012","key":"269_CR30","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0140-6736(77)92097-9","volume":"1","author":"GJ Ayers","year":"1977","unstructured":"Ayers GJ, Burnett D. Drug formulation and salivary phenytoin measurements. Lancet. 1977;1(8012):656.","journal-title":"Lancet."},{"issue":"5","key":"269_CR31","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/01.ftd.0000171869.56817.ae","volume":"27","author":"MD Jones","year":"2005","unstructured":"Jones MD, Ryan M, Miles MV, Tang PH, Fakhoury TA, Degrauw TJ, et al. Stability of salivary concentrations of the newer antiepileptic drugs in the postal system. Ther Drug Monit. 2005;27(5):576\u20139.","journal-title":"Ther Drug Monit."},{"issue":"5","key":"269_CR32","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00007691-199410000-00001","volume":"16","author":"R Gorodischer","year":"1994","unstructured":"Gorodischer R, Burtin P, Hwang P, Levine M, Koren G. Saliva versus blood sampling for therapeutic drug monitoring in children: patient and parental preferences and an economic analysis. Ther Drug Monit. 1994;16(5):437\u201343.","journal-title":"Ther Drug Monit."},{"issue":"8","key":"269_CR33","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1128\/AAC.40.8.1935","volume":"40","author":"CH Koks","year":"1996","unstructured":"Koks CH, Meenhorst PL, Hillebrand MJ, Bult A, Beijnen JH. Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules. Antimicrob Agents Chemother. 1996;40(8):1935\u20137.","journal-title":"Antimicrob Agents Chemother."},{"key":"269_CR34","volume-title":"The Merck manual","author":"R Porter","year":"2006","unstructured":"Porter R. The Merck manual. 19th ed. Whitehouse Station: Merck & Company; 2006.","edition":"19"},{"issue":"4","key":"269_CR35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00007691-200008000-00013","volume":"22","author":"PW Hugen","year":"2000","unstructured":"Hugen PW, Burger DM, de Graaff M, ter Hofstede HJ, Hoetelmans RM, Brinkman K, et al. Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir. Ther Drug Monit. 2000;22(4):437\u201345.","journal-title":"Ther Drug Monit."},{"issue":"11","key":"269_CR36","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1128\/AAC.00423-11","volume":"55","author":"B Damle","year":"2011","unstructured":"Damle B, Varma MV, Wood N. Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use. Antimicrob Agents Chemother. 2011;55(11):5172\u20137.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2\u20133","key":"269_CR37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.forsciint.2004.10.026","volume":"150","author":"JK Aps","year":"2005","unstructured":"Aps JK, Martens LC. Review: the physiology of saliva and transfer of drugs into saliva. Forensic Sci Int. 2005;150(2\u20133):119\u201331.","journal-title":"Forensic Sci Int."},{"issue":"5","key":"269_CR38","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/jcbfm.2012.208","volume":"33","author":"C Salinas","year":"2013","unstructured":"Salinas C, Weinzimmer D, Searle G, Labaree D, Ropchan J, Huang Y, et al. Kinetic analysis of drug-target interactions with PET for characterization of pharmacological hysteresis. J Cereb Blood Flow Metab. 2013;33(5):700\u20137.","journal-title":"J Cereb Blood Flow Metab."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0269-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-015-0269-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0269-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:18:56Z","timestamp":1651796336000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-015-0269-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,25]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["269"],"URL":"https:\/\/doi.org\/10.1007\/s40262-015-0269-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,25]]}}}